URIKA [bioworks]

We help clients re-imagine drug discovery to improve probability of success, accelerate discovery timelines and produce improved therapeutic results. New medicines must progress disease modification towards cure – beyond mere symptom relief. Numerous studies show that genetic validation of novel targets doubles probability of success in clinical trials. Proper biological characterization of targets beyond genetics can quadruple the probability of success in clinical trials. Rich, high resolution understanding of underlying biology informs and improves every phase of the drug discovery, development and commercialization process. We can accelerate the collection of sufficient biological data and knowledge to dramatically accelerate the discovery and validation of novel targets, improve the probability of clinical and commercial success.

Biology by design: Contemporary drug discovery includes but transcends systematic screening to comprehensively map human biology and purposefully design perturbations of the biology that will improve patient health. A growing landscape of therapeutic modalities make previously untargetable targets accessible and provide a broad palette of tools to cleverly modify human biology to desired ends. Our scientists and clients utilize artificial intelligence and machine learning to identify and explore areas of high biological potential and match the appropriate therapeutic modality with the biological opportunity.

We work with clients to improve their pipelines and transform their discovery capabilities. We can engage to produce novel targets or validate existing targets in desired therapeutic areas. We also help clients produce and evaluate their targets by providing better data and tools. We can produce discovery landscape maps highlighting research and discovery activities in an area of biology, in a specific therapeutic modality or therapeutic area. We utilize artificial intelligence and machine learning embedded in our tools and services. We can begin with a novel target engagement, a proof of concept to demonstrate scientific and technology capabilities and we routinely work with clients to ensure institutional adoption of new capabilities and ways of working.